Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448544 | 0.93 | KDM5A (0.47) | MAPTPOLBTP53NPC1RAB9A | |
| SCHEMBL6456813 | 0.89 | TRPV1 (0.49) | MAPTPOLBNPC1RAB9AMEN1 | |
| SCHEMBL6449944 | 0.86 | TDP2 (0.42) | MAPTTP53TRPV1GAATDP1 | |
| SCHEMBL7153693 | 0.82 | MAPT (0.41) | MAPTPOLBTP53NPC1RAB9A | |
| SCHEMBL7047826 | 0.81 | NPC1 (0.50) | MAPTPOLBTP53NPC1RAB9A | |
| SCHEMBL6448718 | 0.81 | TRPV1 (0.47) | MAPTPOLBMEN1KMT2ATRPV1 | |
| SCHEMBL6450199 | 0.81 | KDM4E (0.48) | MAPTPOLBTP53NPC1RAB9A | |
| SCHEMBL6450555 | 0.79 | NPC1 (0.50) | MAPTTP53NPC1RAB9AMEN1 | |
| SCHEMBL6449735 | 0.79 | TDP2 (0.41) | MAPTTP53TRPV1KDM5AKDM4D | |
| SCHEMBL6452535 | 0.79 | CASP3 (0.60) | MAPTTP53NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | MAPT 2805/4885POLB 2806/4885TP53 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.